Cereno Scientific announces issuance of European patent for drug candidate CS585
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS585’s second patent family has obtained a formally issued patent in Europe, one of the largest markets in cardiovascular disease. This strengthens and broadens the intellectual property rights (IPR) for CS585 which currently is in a preclinical development program in collaboration with the University of Michigan.“I am pleased to report that the first patent in Europe for our preclinical drug candidate CS585 has now been formally issued by the European Patent Office as a final step of the approval process. This is a great